期刊
BIOLOGICAL & PHARMACEUTICAL BULLETIN
卷 34, 期 5, 页码 755-759出版社
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.34.755
关键词
systemic lupus erythematosus; mycophenolic acid; pharmacokinetics; mycophenolic acid 7-O-glucuronide
The aim of this study was to identify factors affecting the pharmacokinetics of mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG) in systemic lupus erythematosus (SLE) patients. Thirty-one SLE patients in remission maintenance phase treated with mycophenolate mofetil (median 1500 mg/d) and prednisolone and followed-up for up to 56 months (median 13 months) were enrolled. Creatinine clearance and metal medication were significant predictors accounting for interindividual variability in the dose-normalized predose plasma concentration (C-0) of MPA (adjusted R-2=0.305, p=0.01) in a multivariate analysis. Dose-normalized MPAG C-0 was significantly correlated with only creatinine clearance (adjusted R-2=0.135, p=0.03). The free fraction of MPA was significantly correlated with only serum albumin (adjusted R-2=0.700, p<0.01). The free fraction of MPAG was significantly correlated with serum albumin, metal medication, and age (adjusted R-2=0.598, p=0.02). In conclusion, renal function and co-administered metal influenced the pharmacokinetics of MPA and MPAG in SLE patients in remission maintenance phase.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据